Is vonjo used for patients with low platelets?

Is Vonjo (pacritinib) used when platelet counts are low?

Yes. Vonjo is designed for patients with myelofibrosis who have low platelet counts, which is one of its key uses. It is specifically used in people with intermediate- or high-risk primary or secondary myelofibrosis (including post–polycythemia vera or post–essential thrombocythemia) and platelet counts below a defined threshold (not based on being able to tolerate standard dosing with higher platelets). [1]

What platelet level qualifies, and how is it different from other myelofibrosis drugs?

Vonjo is one of the myelofibrosis treatments that targets the unmet need of patients with thrombocytopenia (low platelets). Other drugs used in myelofibrosis often have platelet-count restrictions that limit use in patients with very low platelets. Vonjo’s labeling and development focus on that group. [1]

Who should not use Vonjo because of platelets or related risk?

Patients with myelofibrosis may still need careful eligibility screening beyond platelet count alone, because dosing and safety can depend on baseline blood counts and overall health. The prescribing information is the authority for inclusion/exclusion criteria and dose adjustments. [1]

Where does the “low platelets” use come from?

Vonjo’s clinical program and regulatory pathway centered on efficacy and safety in people with myelofibrosis and low platelet counts, including those who are less able to take other therapies due to thrombocytopenia. [1]

Sources:
[1] https://www.drugpatentwatch.com/vonjo